As Sessions Cracks Down on Weed, Maker of Fentanyl Is Selling Synthetic THC

Fred Hamble
Jan 04, 2018

Attorney General Jeff 'Beauregard' Sessions rescinded a trio of memos from the Obama administration on Thursday that had previously set a standard for federal non-interference with state-approved marijuana sales.

In a statement released by the Department of Justice, Sessions made it clear that "The War on Drugs" is back on, and will be starting with marijuana.

"It is the mission of the Department of Justice to enforce the laws of the United States, and the previous issuance of guidance undermines the rule of law and the ability of our local, state, tribal, and federal law enforcement partners to carry out this mission. Therefore, today's memo on federal marijuana enforcement simply directs all U.S. Attorneys to use previously established prosecutorial principles that provide them all the necessary tools to disrupt criminal organizations, tackle the growing drug crisis, and thwart violent crime across our country."

Suspicious from his statement, however, was the continued legality of Dronabinol, a synthetic THC nasal spray that was quietly granted a Schedule II classification during the Thanksgiving weekend. The classification means the government officially recognizes its medicinal potential and will allow it to be prescribed, sold and federally regulated.

Non-synthetic THC, which is the active chemical compound in marijuana, remains classified as a Schedule I drug. As such, the government believes it is potentially dangerous and has no medicinal value.

Now states whose residents have voted to make it legal, may once again face the full force of federal drug enforcement.

Meanwhile, Insys Therapeutics, the company which developed Dronabinol, will now enjoy a monopoly on the treatment of cancer patients who experience nausea from chemotherapy thanks to the DEA. 

Insys also manufactures fentanyl, a painkiller that is 50 times stronger than heroin that is driving the national opioid crisis that Sessions seems far less concerned about.

The company is now working on a synthetic version of Cannabidiol to treat a variety of ailments in children. That substance, which is also an oral solution, is currently in various stages of clinical trials in the FDA’s approval process. It is anticipated to also be granted Schedule II classification.

So in the near future, while you will face years in prison for smoking marijuana, doctors will be able to write a $2,000 prescription for your children to get THC that was made in a test tube.